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ABSTRACT 
 
Comparative genomics of clinical isolates of Pseudomonas fluorescens, including the discovery 
of a novel disease-associated subclade. 
by 
Brittan Starr Scales 
Chair: Gary Huffnagle 
Abstract title: Comparative genomics of clinical isolates of Pseudomonas fluorescens, including 
the discovery of a novel disease-associated subclade. 
 
Taxonomically, there are over 52 Pseudomonas species that group within the Pseudomonas 
fluorescens species-complex. They are gram-negative bacteria (gammaproteobacteria) that 
have the ability to flourish in many different environmental niches due their metabolic 
adaptability. Prior to beginning the project described in this dissertation, we had identified (using 
culture-independent analysis) that the lung microbiome of patients with severe chronic 
obstructive pulmonary disease (COPD) contained abundant levels of P. fluorescens. This 
finding was highly unexpected because P. fluorescens colonization had not been previously 
reported in chronic respiratory disease (human or veterinary).  Furthermore, there was no 
taxonomic or genome information on clinical P. fluorescens strains in the published literature or 
NCBI database. This raised the question of whether there were differences between P. 
fluorescens strains isolated from clinical vs. environmental sources.  To begin to address this 
question, I sequenced a collection of Pseudomonas spp. isolates from individuals with chronic 
lung disease, which included 22 clinical P. fluorescens strains. Twelve of the 22 could be 
grouped within previously defined subclades I, II and III of the P. fluorescens species-complex. 
However, the other 10 strains were distinct and could be clustered as a phylogenetically unique 
fourth subclade, which lacked any representative genomes (clinical or environmental) in the 
  xi 
NCBI database. I performed additional comparative genomic analyses on all four subclades in 
order to identify genomic attributes that were associated with growth in humans (vs. the 
environment). Subclade III clinical isolates were almost indistinguishable from environmental 
isolates; however, the clinical isolates contained additional homologues of genes involved in 
metal toxicity resistance, an attribute that has been reported for chronic antibiotic exposure, 
such as would occur in the cystic fibrosis lung.  In sharp contrast, subclade IV strains displayed 
marked reductions in genome size, gene diversity and GC content, as well as containing all of 
the elements for a Ysc family type III secretion system that was extremely similar to that found 
in P. aeruginosa.  Furthermore, our subclade IV strains, collected from geographic locations 
across the U.S., had a very high level of shared nucleotide identity and a small accessory 
genome, suggesting that they may have evolved from living in multi-trophic environments to a 
life in a much narrower niche, perhaps human airways. We also identified that some colonies of 
inbred mice contained indigenous P. fluorescens in their lung microbiome (subclade III) and 
chronic inflammation was associated with an outgrowth of P. fluorescens. Expanding my 
analysis to human respiratory disease, I found an increase in P. fluorescens (largely subclade 
III) in lung samples from multiple diseases (COPD, IPF and lung transplant) but not healthy 
subjects.  Altogether, these studies reveal that P. fluorescens is an under-appreciated colonizer 
of humans, particularly in the context of pulmonary inflammation, and lay the groundwork for 
future studies delineating the contribution and molecular mechanisms of this host-microbe 
interaction. 
 
